Part Three
Why Progress Stalls
The survey suggests that technology itself is no longer the primary barrier to maturity.
In fact, 51% of respondents reported being satisfied with the pace of digital adoption within their organizations. The challenge is increasingly organizational rather than technological.
Governance emerged as a recurring constraint. Respondents frequently referenced lengthy approval processes, multiple decision layers, unclear ownership, and competing priorities. Better information may expose risks earlier, but governance ultimately determines how quickly organizations can act.
Q: How satisfied are you with the time it currently takes your organization to adopt new technologies and become more digitally mature?
"Digital maturity in pharmaceutical supply chains is no longer defined by technology adoption alone. Many organisations now have access to better tools, but value depends on whether those tools are supported by clear governance, integrated systems, and accountable decision-making. In a regulated environment, validation and compliance will always shape the pace of change. The challenge is to modernise without adding complexity, connecting technology, processes, and ownership so organisations can act faster while maintaining control."
Nigel Cryer Managing Director & Senior Consultant Bluciela-Lifesciences
Legacy systems present a second challenge. Many organizations continue to operate across fragmented technology landscapes that were designed to support internal processes rather than cross-company collaboration. Data often exists but does not move efficiently between systems or stakeholders at the point of decision.
Q: What are the main blockers for your organization in accelerating/adopting new technologies faster?
"Legacy systems that are hard to integrate with new technology can slow implementation."
"It is challenging to integrate newer digital technologies with legacy systems."
"Our organization faces challenges in aligning new technologies with existing legacy systems, which slows down the adoption process."
"Many operations still depend on legacy systems which makes new adoption harder."
Finally, regulatory requirements continue to shape adoption decisions. Validation obligations, compliance requirements, and cybersecurity concerns create a higher threshold for change than in many other industries. While this caution is appropriate, it also contributes to slower implementation cycles.
Collectively, these barriers explain why many organizations remain caught between digital capability and operational maturity.
"Regulatory and compliance requirements can limit how new technologies are implemented."
"Regulatory and compliance requirements slow down the adoption of new technologies."
"Regulatory and data privacy rules require extra checks before adopting new technologies."
"The implementation of new technologies is slowed down by regulatory validation procedures."
Resources and Expertise Remain Limited
Technology adoption depends on more than software investment.
Budget constraints, competing priorities, limited IT resources, and shortages of technical expertise were cited as barriers to accelerating digital transformation. Several respondents also referenced difficulties in demonstrating return on investment, particularly for emerging technologies where benefits can be difficult to quantify before deployment.
Even when organisations recognise the value of new technologies, the resources required to deploy, manage, and scale them can slow progress considerably.
Risk Aversion Is Built Into the System
The final barrier is not technological or organisational. It is structural.
Pharmaceutical supply chains operate in highly regulated environments where the consequences of failure are significant. Product quality, patient safety, regulatory compliance, and data security all influence technology adoption decisions.
Respondents frequently referenced regulatory validation requirements, compliance obligations, cybersecurity concerns, and uncertainty around new technologies as reasons for cautious implementation.
This caution is often rational. New technologies must not only demonstrate value; they must also demonstrate reliability, compliance, and operational resilience.
The Next Barrier Is Operational
As digital capabilities mature, competitive advantage is shifting.
Success will depend less on generating visibility and more on translating insight into action - enabling faster decisions, stronger collaboration and more adaptive responses to disruption.
This raises an important question: What does the next generation of pharmaceutical supply chain operating models look like?
The next chapter explores the capabilities and organisational structures that respondents believe will define that future.
